EGFR and neoplasm: Because activation of IGF-1R-mediated signaling has been associated with cancer cell resistance to anti-EGFR therapy and also to RT 16,17, cotargeting EGFR and IGF-1R pathways in conjunctions with RT is expected to yield a better outcome in controlling tumor growth.